Blueprint Medicines (NASDAQ:BPMC) Given New $129.00 Price Target at Morgan Stanley
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective hoisted by equities research analysts at Morgan Stanley from $102.00 to $129.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s price target points to a potential upside of 0.90% from […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective hoisted by equities research analysts at Morgan Stanley from $102.00 to $129.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s price target points to a potential upside of 0.90% from […]
